ENDRA Life Sciences Inc.

Good afternoon, ladies and gentlemen, and welcome to the Endra Life Sciences Inc. Fourth Quarter 2020 Financial Results Conference Call. At this time, all participants have been placed on a listen-only mode, and we will open the floor for your questions and comments after the presentation. It is now my pleasure to turn the floor over to your host, Yvonne Briggs. Ma'am, the floor is yours.

Thank you, Operator. This is Yvonne Briggs with LHA, Endra Life Sciences Investor Relations Firm. Good afternoon and welcome to NDRA's fourth quarter 2020 business update and financial results conference call. Earlier today, NDRA issued a press release on this topic, and for those of you who don't have a copy, you can access it in the investor section of NDRA's website at NDRAinc.com. Before we begin, please note that today's discussion will include forward-looking statements, all statements other than statements of historical facts, including statements regarding the company's strategies, Financial Condition, Operations, Costs, Plans, and Objectives, as well as anticipated results of development and commercialization efforts, the timing of clinical studies, potential partnership opportunities, and expectations regarding receipt of required regulatory clearances and product launches, are forward-looking statements. Except as otherwise required by federal securities laws, the company disclaims any obligation to update or revise any forward-looking statements. Please refer to the company's Form 10-K for the 2020 fiscal year filed with the SEC for more information about risks and uncertainties related to forward-looking statements. In terms of the structure of today's call, Francois Michelon, Chairman and Chief Executive Officer, will begin the prepared remarks, followed by Renaud Malaberti, NDRA's Chief Commercial Officer, and then David Wells, Chief Financial Officer, Michael Thornton, NDRA's Chief Technology Officer, will join us for the Q&A portion. With that said, I will now turn the call over to Francois Michelon. Francois?

Thank you, Yvonne. Good afternoon, everyone, and thank you for joining us today to review Endra's fourth quarter 2020 financial results and business update. Despite the headwinds of COVID-19, I'm very pleased with the progress Endra made in 2020 and so far this year. We accomplished several key regulatory and commercial milestones,